{"id":21906,"date":"2023-02-21T16:27:00","date_gmt":"2023-02-21T08:27:00","guid":{"rendered":"https:\/\/flcube.com\/?p=21906"},"modified":"2025-01-18T21:29:35","modified_gmt":"2025-01-18T13:29:35","slug":"suzhou-porton-biologics-partners-with-yinjia-biosciences-for-cgt-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21906","title":{"rendered":"Suzhou Porton Biologics Partners with Yinjia Biosciences for CGT Development"},"content":{"rendered":"\n<p>China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has struck a partnership with Yinjia Biosciences, a protein reagents and diagnostic products developer based in Shanghai. The agreement aims to enhance the development and industrialization of cell and gene therapy (CGT) by leveraging the strengths of both companies.<\/p>\n\n\n\n<p><strong>Partnership Details<\/strong><br>Under the agreement, Yinjia Bio will provide Porton with high-quality core key protein raw materials and testing reagent product services related to quality control and evaluation systems. Both parties will jointly promote the development and industrialization of CGT, marking a significant step in advancing this promising field of medicine.<\/p>\n\n\n\n<p><strong>Porton&#8217;s CDMO Platform<\/strong><br>Founded in 2018, Porton boasts an end-to-end gene and cell therapy CDMO service platform. The platform covers a broad range of therapeutic areas, including plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy, and live bacterial therapy. This comprehensive service offering positions Porton as a leading provider in the CGT space.<\/p>\n\n\n\n<p><strong>Yinjia Bio&#8217;s Product Portfolio<\/strong><br>Yinjia Bio, established in 2020, has developed over 50 high-end proteins, including a calcium-regulated nerve phosphatase (PP2B), adenosyl se, non-viral carrier-specific protein for cell therapy, and a novel antibody for concomitant diagnosis of liver cancer and gastric cancer. The company&#8217;s products also cover cell therapies, mRNA vaccines, closed-loop RNA, new drug research and development, and molecular diagnosis and concomitant diagnosis of new tumor drugs.<\/p>\n\n\n\n<p><strong>Strategic Implications<\/strong><br>The partnership between Suzhou Porton Biologics and Yinjia Biosciences is a strategic move to combine expertise in protein reagents and CGT development. By collaborating, the two companies aim to accelerate the commercialization of innovative therapies and improve patient access to advanced treatments. This initiative is expected to enhance the competitive position of both companies in the global biotechnology market and contribute to the broader goal of advancing medical science.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has struck a partnership&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,77,19,66,628,3190],"class_list":["post-21906","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-cell-therapy","tag-cro-cmo-cdmo","tag-gene-therapy","tag-porton-biologics","tag-yinjia-biosciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Suzhou Porton Biologics Partners with Yinjia Biosciences for CGT Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has struck a partnership with Yinjia Biosciences, a protein reagents and diagnostic products developer based in Shanghai. The agreement aims to enhance the development and industrialization of cell and gene therapy (CGT) by leveraging the strengths of both companies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21906\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Suzhou Porton Biologics Partners with Yinjia Biosciences for CGT Development\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21906\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-21T08:27:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-18T13:29:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21906#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21906\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Suzhou Porton Biologics Partners with Yinjia Biosciences for CGT Development\",\"datePublished\":\"2023-02-21T08:27:00+00:00\",\"dateModified\":\"2025-01-18T13:29:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21906\"},\"wordCount\":310,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Cell-therapy\",\"CRO \\\/ CMO \\\/ CDMO\",\"Gene therapy\",\"Porton Biologics\",\"Yinjia Biosciences\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21906#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21906\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21906\",\"name\":\"Suzhou Porton Biologics Partners with Yinjia Biosciences for CGT Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-02-21T08:27:00+00:00\",\"dateModified\":\"2025-01-18T13:29:35+00:00\",\"description\":\"China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has struck a partnership with Yinjia Biosciences, a protein reagents and diagnostic products developer based in Shanghai. The agreement aims to enhance the development and industrialization of cell and gene therapy (CGT) by leveraging the strengths of both companies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21906#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21906\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21906#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Suzhou Porton Biologics Partners with Yinjia Biosciences for CGT Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Suzhou Porton Biologics Partners with Yinjia Biosciences for CGT Development - Insight, China&#039;s Pharmaceutical Industry","description":"China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has struck a partnership with Yinjia Biosciences, a protein reagents and diagnostic products developer based in Shanghai. The agreement aims to enhance the development and industrialization of cell and gene therapy (CGT) by leveraging the strengths of both companies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21906","og_locale":"en_US","og_type":"article","og_title":"Suzhou Porton Biologics Partners with Yinjia Biosciences for CGT Development","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=21906","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-02-21T08:27:00+00:00","article_modified_time":"2025-01-18T13:29:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21906#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21906"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Suzhou Porton Biologics Partners with Yinjia Biosciences for CGT Development","datePublished":"2023-02-21T08:27:00+00:00","dateModified":"2025-01-18T13:29:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21906"},"wordCount":310,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Cell-therapy","CRO \/ CMO \/ CDMO","Gene therapy","Porton Biologics","Yinjia Biosciences"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21906#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21906","url":"https:\/\/flcube.com\/?p=21906","name":"Suzhou Porton Biologics Partners with Yinjia Biosciences for CGT Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-02-21T08:27:00+00:00","dateModified":"2025-01-18T13:29:35+00:00","description":"China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has struck a partnership with Yinjia Biosciences, a protein reagents and diagnostic products developer based in Shanghai. The agreement aims to enhance the development and industrialization of cell and gene therapy (CGT) by leveraging the strengths of both companies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21906#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21906"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21906#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Suzhou Porton Biologics Partners with Yinjia Biosciences for CGT Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21906","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21906"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21906\/revisions"}],"predecessor-version":[{"id":21908,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21906\/revisions\/21908"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21906"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21906"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21906"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}